The pharma and biotech company said it plans to use the genome editing technology in its bioproduction products and services and in stem cells for research.
The method, called negative enrichment, protects DNA regions of interest prior to degrading the surrounding DNA, making the target fragments easier to read.
Even as He Jiankui expressed pride in the work he had done to alter the CCR5 genes of twin embryos, researchers and ethicists decried him as misguided.
The investigators showed that template-free Cas9 editing is capable of repair to a predicted genotype, allowing for correction of disease-associated mutations.
The MIT team found that a previously uncharacterized Cas9 from Streptococcus canis has fewer PAM requirements than the more widely used S. pyogenes Cas9.
A team led by Walter and Eliza Hall Institute researchers found that ovarian tumors with complete BRCA1 methylation and silencing were more susceptible to treatment.
Under the terms of the agreements, Thermo Fisher obtains global non-exclusive rights to products, tools, and research services involving the technologies.
